Label: CYSTOGRAFIN- diatrizoate meglumine injection, solution

  • NDC Code(s): 0270-0149-57, 0270-0149-60
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated April 15, 2018

If you are a consumer or patient please visit this version.


    For retrograde cystourethrography
    Not intended for intravascular injection


    Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light.


    Cystografin is indicated for retrograde cystourethrography.


    This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.


    Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents.

    A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.


    Safe and effective use of this preparation depends upon proper dosage, correct technique, adequate precautions, and readiness for emergencies.

    Retrograde cystourethrography should be performed with caution in patients with a known active infectious process of the urinary tract.

    Sterile technique should be employed in administration. During administration, care should be taken to avoid excessive pressure, rapid or acute distention of the bladder, and trauma.

    Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.

    Pregnancy—Teratogenic Effects:

    Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin should be administered to a pregnant woman only if clearly needed.


    Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria.

    If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.

    Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.


    Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended.

    Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below.

    Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full.

    Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.

    Dilution Table
    100 mL Bottle 
    Sterile Water or Sterile Saline Added % Diatrizoate Meglumine w/v% Organically Bound Iodine w/v Total Volume
    0 mL 30.0 14.1 100 mL
    25 mL 24.0 11.3 125 mL
    50 mL 20.09.4 150 mL
    67 mL 18.0 8.5 167 mL
    300 mL Bottle 
    Sterile Water or Sterile Saline Added 
    0 mL 30.0 14.1 300 mL
    50 mL 25.7 12.1 350 mL

    Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively.


    Store at 20-25°C (68-77°F) [See USP]. Protect from light.

    Also Available

    Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is also available, as a 300 mL fill in a 400 mL bottle.


    Revised April 2018 

    Rx only

    Manufactured for
    Bracco Diagnostics Inc.
    Monroe Township, NJ 08831

    by Patheon Italia S.p.A.
    03013 Ferentino (Italy)


    Cystografin 100 mL Label
    NDC 0270-0149-60

    100 mL Label
    diatrizoate meglumine injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0270-0149
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    diatrizoate meglumine (UNII: 3X9MR4N98U) (diatrizoic acid - UNII:5UVC90J1LK) diatrizoate meglumine300 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    edetate disodium (UNII: 7FLD91C86K) 0.4 mg  in 1 mL
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0270-0149-6010 in 1 PACKAGE11/03/1970
    1100 mL in 1 BOTTLE; Type 0: Not a Combination Product
    2NDC:0270-0149-5710 in 1 PACKAGE11/03/1970
    2300 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - BRACCO DIAGNOSTICS INC (849234661)
    Registrant - BRACCO DIAGNOSTICS INC (849234661)
    NameAddressID/FEIBusiness Operations
    PATHEON ITALIA SPA434078638MANUFACTURE(0270-0149) , ANALYSIS(0270-0149)
    NameAddressID/FEIBusiness Operations
    Justesa Imagen, S.A.U477020325API MANUFACTURE(0270-0149)